Table 3:
Multivariable Cox Regression Model for Mortality | ||||
---|---|---|---|---|
N | HR | 95% CI | p-value | |
Diagnosis/Phase | ||||
ALL CR1* | 15 | 1.0 | -- | -- |
ALL CR2/Advanced | 106 | 2.6 | (1.4, 4.9) | 0.002 |
AML CR1/MDS | 48 | 2.2 | (1.1, 4.3) | 0.028 |
AML CR2/AML Advanced | 63 | 2.9 | (1.5, 5.4) | 0.001 |
1st HCT Preparative Regimen | ||||
TBI-based | 198 | 1.8 | (1.0, 3.1) | 0.052 |
Chemo-based* | 23 | 1.0 | -- | -- |
RIC | 11 | 4.1 | (1.9, 9.1) | <0.001 |
1st HCT to relapse (months) | ||||
0–6 | 114 | 3.2 | (2.2, 4.7) | <0.001 |
>6–12 | 66 | 2.1 | (1.4, 3.2) | <0.001 |
>12+ | 52 | 1.0 | -- | -- |
Reference group
Note: Variables examined for potential inclusion in model were: Sex, Year of HCT, Time from HCT to relapse, Donor type, Diagnosis/Phase at HCT, Conditioning regimen, MRD status at relapse, Time from diagnosis to HCT, Age at HCT, Age at relapse.
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CHEMO, chemotherapy; CI, confidence interval; GVHD, graft-vs-host disease; HCT, hematopoietic cell transplant; HR, hazard ratio; IS, immune suppression; MDS, myelodysplastic syndrome; RIC, reduced intensity conditioning; TBI, total body irradiation.